Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advancing a Differentiated Next-Gen GLP-1 Platform

SureNano Advances GLP-1 Pipeline Amidst Dilution Concerns and Clinical Milestones

By The Northwire Desk — AI Analysis May 12, 2026 · 08:30 SURE · 0.22 SureNano Science Ltd. - New Listing
Executive Summary
  • Most Recent Release (May 12, 2026): Media coverage by BioMedWire highlights SureNano's subsidiary GlucaPharm Inc. and its lead asset GEP-44. The editorial reiterates the potential for improved efficacy, tolerability, and non-injectable delivery compared to existing GLP-1 treatments.
  • Preceding Release (May 11, 2026): Confirms preclinical studies showing GEP-44 provides ~15% weight loss vs ~9% for liraglutide and ~39% food intake reduction. Development is advancing through IND-enabling studies toward Phase I clinical trials in Australia.
  • Historical Progression:
    • Nov 2025: LOI to acquire GlucaPharm Inc. announced; Private Placement ($1.25M) initiated.
    • Dec 2025: Private Placement closed ($1.25M raised, warrants at $0.35).
    • Feb 2026: Acquisition of GlucaPharm completed (8.1M shares + warrants issued); Dr. Pandey appointed CSO.
    • Apr 2026: FDA IND-enabling toxicology studies initiated with LabCorp; Ibogaine IP discussions started; Marketing agreements signed ($10k-$29k fees).
Material Impact
  • News Impact: The May 12 media coverage is a follow-up to the May 11 preclinical data release. It does not introduce new financial or clinical milestones but reinforces the existing narrative regarding GEP-44's differentiation in the crowded GLP-1 market.
  • Expectations vs. Reality: The preclinical metrics (15% weight loss) align with previous announcements made during the acquisition phase and April toxicology initiation. There are no surprises or misses relative to prior guidance.
  • Materiality Determination: This is classified as Routine - Positive because it serves as marketing validation of previously disclosed data rather than a transformative event like a Phase 1 readout, partnership deal, or regulatory approval. The market likely priced in the preclinical success during May 11; this release maintains momentum without shifting valuation materially.
  • Comparison to History: Unlike the February acquisition (Material - Positive), which fundamentally changed the company's asset base, these updates are incremental steps within the established development plan.
SURE · Price
Company Overview
  • Company Name: SureNano Science Ltd. (CSE: SURE / OTCQB: SURNF).
  • Core Business: Transitioning from surfactant distribution to pharmaceutical development via subsidiary GlucaPharm Inc.
  • Flagship Project: GEP-44, a patented triple agonist peptide licensed from Syracuse University.
    • Mechanism: Targets GLP-1 and PYY receptors Y1/Y2 for glucose metabolism and appetite suppression.
    • Therapeutic Area: Obesity, Type 2 Diabetes (T2DM), metabolic care.
    • Delivery Platform: Developing oral, sublingual, and intranasal options to avoid injections.
  • Development Stage: IND-enabling studies completed/ongoing; Phase I human trials planned in Australia pending CTN submission.
Read the original news release →

More from SureNano Science Ltd. - New Listing

May 15, 2026 · 08:30

SureNano Science Ltd.

Other May 14, 2026 · 08:30

SureNano’s GLP-1 Dreams Get Media Splash, But Stock Still Trades Below Financing Strike

Other May 13, 2026 · 08:30

SureNano Advances GLP-1 Pipeline Amidst Dilution Concerns and Clinical Milestones

Production / Operations May 11, 2026 · 08:30

SureNano Advances GLP-1 Pipeline Amidst Cash Burn Concerns

Other Apr 24, 2026 · 08:01

SureNano Advances GLP-1 Pipeline Amidst Marketing Spend and Dilution Concerns

Other Feb 23, 2026 · 21:40

Surenano Science closes acquisition of GlucaPharm

M&A / Property